

**TOWNSEND  
and  
TOWNSEND  
and  
CREW**

LLP

Denver, Colorado  
Tel 303 571-4000

Palo Alto, California  
Tel 650 326-2400

Seattle, Washington  
Tel 206 467-9600

Walnut Creek, California  
Tel 925 472-5000

San Francisco

Two Embarcadero Center  
Eighth Floor  
San Francisco  
California 94111-3834  
Tel 415 576-0200  
Fax 415 576-0300

**FACSIMILE COVER SHEET**

Date: <b>March 15, 2001</b>	Client & Matter Number : <b>015542-002330US</b>	No. Pages (including this one): <b>7</b>
To: <b>Examiner David Lukton USPTO - Art Unit 1653</b>	At Fax Number: <b>1-703-308-4242</b>	Confirmation Phone Number:

From : Eric J. Baude

**OFFICIAL**

(4519)

Message:

**FAX RECEIVED**

**MAR 15 2001**

**GROUP 1600**

Original Will:	<input type="checkbox"/> BE SENT BY MAIL	<input type="checkbox"/> BE SENT BY FEDEX/OVERNIGHT COURIER	<input type="checkbox"/> BE SENT BY MESSENGER	<input checked="" type="checkbox"/> NOT BE SENT
----------------	--	---	---	---

Faxed:

Return to: Dana Kane - (4658)

If you have problems with reception please call Fax Services at extension **4659**

**Important**


This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and/or exempt from disclosure by applicable law or court order. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the United States Postal Service. Thank you.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile  
transmitted to the Patent and Trademark Office

on March 15, 2001.

Date

  
\_\_\_\_\_  
Signature

Dana Kane

\_\_\_\_\_  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this  
certificate must identify each submitted paper.

Response to Restriction Requirement in 09/506,430.

I hereby certify that this correspondence is being sent by facsimile transmission to: Examiner D. Lukton, Art Unit 1653, United States Patent and Trademark Office, Washington, D.C. 20231

at Fax No.: 703-308-4242

On March 15, 2001

TOWNSEND and CREW LLP

By: Dana Kane

PATENT  
Attorney Docket No.: 015542-002330US  
Client Reference No.: 121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Green *et al.*

Application No.: 09/506,430

Filed: February 17, 2000

For: PHARMACEUTICAL  
ANGIOSTATIC DIPEPTIDE  
COMPOSITIONS AND METHODS OF  
USE THEREOF

Examiner: Lukton, David

Art Unit: 1653

RESPONSE TO RESTRICTION  
REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed March 1, 2001. In the Office Action, the Examiner alleged that the previous response to the Restriction Requirement was incomplete and required election of a peptide species and a specific disorder species.

REMARKS

Claims 18-42 are pending in this application and presented for examination (see attached Appendix), as claims 1-17 have been canceled by the Preliminary Amendment filed in this application. In response to the restriction requirement, Applicants elect, with traverse, Group 1, drawn to a method of treating a subject afflicted with a condition that includes G1, but excludes G2 and G3, said method comprising administering any peptide, including G5, provided that G6 is excluded. Claims readable thereon include claims 18-35, 38 and 39. Applicants elect, with traverse, pyroGlu-Trp (pGlu-Trp-OH) as the peptide species. Applicants elect, with traverse, malignant tumors as the specific disorder that is the target of the treatment. Reconsideration is respectfully requested.